• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Allarity Therapeutics Inc.

    4/30/25 5:28:37 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email
    DEFA14A 1 allr20250430_defa14a.htm FORM DEFA14A allr20250430_defa14a.htm

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     


     

    SCHEDULE 14A

     


     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934
    (Amendment No. )

    Filed by the Registrant

    ☒

    Filed by a Party other than the Registrant

    ☐

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

     

    Allarity Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     


    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

    notice01.jpg

     

     

     

     

    notice02.jpg

     

     
    Get the next $ALLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      11/13/24 9:24:34 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Allarity Therapeutics Inc.

      SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)

      8/29/24 3:57:47 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      2/12/24 9:52:15 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    SEC Filings

    See more
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/5/25 8:09:43 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/3/25 8:05:26 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      5/13/25 8:01:52 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Financials

    Live finance-specific insights

    See more
    • Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

      - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s

      5/14/24 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Reports Third Quarter 2022 Financial Results

      Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:

      11/15/22 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

      Press release        Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. ("Oncoheroes"), a clini

      1/3/22 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:10:53 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Benjamin Laura

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:09:04 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Mclaughlin Gerald W.

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:07:13 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action

           TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced a research collaboration with the Indiana Biosciences Research Institute (IBRI). The collaboration is aimed primarily at further deepening the Company's mechanistic understanding of the dual mechanism of action of stenoparib. Stenoparib is a novel, orally available small-molecule inhibitor of PAR

      6/4/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

               TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP®) companion diagnostic (CDx) toward potential FDA approval. It builds on encouraging data from Allarity'

      6/2/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

               TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced the Company's CEO, Thomas Jensen, will deliver a company overview focused on stenoparib and the Company's DRP® companion diagnostic platform and conduct one-on-one meetings at the Pharma Partnering Summit US. The event is a business development and licensing conference for executives of biotechnology and pharmaceutical companies, taking place May 14–15 in San Diego, CA. Registrants can request one-on-one meetings with Tho

      5/12/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

        Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio

      11/14/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

      Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk's U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced seve

      10/3/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      - New CFO Brings Multiple Years of Experience from Biotech Companies- As Part of the New Hire, the Company Issues Inducement Grants Boston (September 13, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the appointment of Alex Epshinsky as the Company's new Chief Financial Officer (CFO), and that the Company has granted equity awards on September 12, 2024 as a material inducement to the employment of Mr. Epshinsky. Mr. Epshinsky is a Chartered Public Accountant (CPA) and brings nearly a decade of financial leadership experience in the biotech and

      9/13/24 8:45:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care